Suppr超能文献

用丙型肝炎病毒样颗粒进行免疫接种可在非人灵长类动物中诱导体液免疫和细胞免疫反应。

Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates.

作者信息

Jeong Sook-Hyang, Qiao Ming, Nascimbeni Michelina, Hu Zongyi, Rehermann Barbara, Murthy Krishna, Liang T Jake

机构信息

Liver Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

出版信息

J Virol. 2004 Jul;78(13):6995-7003. doi: 10.1128/JVI.78.13.6995-7003.2004.

Abstract

We have previously reported the production of hepatitis C virus-like particles (HCV-LP) using a recombinant baculovirus containing the cDNA of the HCV structural proteins (core, E1, and E2). These particles resemble the putative HCV virions and are capable of inducing strong and broad humoral and cellular immune responses in mice. Here we present evidence on the immunogenicity of HCV-LP and the effects of novel adjuvant systems in a nonhuman primate model, the baboon. Three groups of four baboons were immunized with HCV-LP, HCV-LP and adjuvant AS01B (monophosphoryl lipid A and QS21), or HCV-LP and the combination of AS01B and CpG oligodeoxynucleotides 10105. After four immunizations over an 8-month period, all animals developed HCV-specific humoral and cellular immune responses including antibodies to HCV structural proteins and gamma interferon(+) (IFN-gamma(+))CD4(+) and IFN-gamma(+)CD8(+) T-cell responses. The immunogenicity of HCV-LP was only marginally enhanced by the use of adjuvants. The overall HCV-specific immune responses were broad and long lasting. Our results suggest that HCV-LP is a potent immunogen to induce HCV-specific humoral and cellular immune responses in primates and may be a promising approach to develop novel preventive and therapeutic modalities.

摘要

我们之前报道过,利用一种含有丙型肝炎病毒(HCV)结构蛋白(核心蛋白、E1蛋白和E2蛋白)cDNA的重组杆状病毒生产丙型肝炎病毒样颗粒(HCV-LP)。这些颗粒类似于推测的HCV病毒体,能够在小鼠体内诱导强烈且广泛的体液免疫和细胞免疫反应。在此,我们展示了关于HCV-LP免疫原性以及新型佐剂系统在非人灵长类动物模型狒狒中的作用的证据。将三组各四只狒狒分别用HCV-LP、HCV-LP与佐剂AS01B(单磷酰脂质A和QS21)或HCV-LP与AS01B和CpG寡脱氧核苷酸10105的组合进行免疫。在8个月内进行四次免疫后,所有动物都产生了HCV特异性体液免疫和细胞免疫反应,包括针对HCV结构蛋白的抗体以及γ干扰素阳性(IFN-γ(+))CD4(+)和IFN-γ(+)CD8(+) T细胞反应。使用佐剂仅略微增强了HCV-LP的免疫原性。总体HCV特异性免疫反应广泛且持久。我们的结果表明,HCV-LP是一种在灵长类动物中诱导HCV特异性体液免疫和细胞免疫反应的有效免疫原,可能是开发新型预防和治疗方法的一种有前景的途径。

相似文献

8
Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees.
Proc Natl Acad Sci U S A. 2007 May 15;104(20):8427-32. doi: 10.1073/pnas.0702162104. Epub 2007 May 7.

引用本文的文献

1
Targets of protective immunity and opportunities in hepatitis C virus vaccine development.
Nat Rev Immunol. 2025 Sep 12. doi: 10.1038/s41577-025-01215-9.
2
Recent Advances in Antiviral Drug Delivery Strategies.
AAPS PharmSciTech. 2025 Mar 4;26(3):73. doi: 10.1208/s12249-025-03053-3.
4
[Development approaches for vaccines against hepatitis C virus infections].
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2022 Feb;65(2):183-191. doi: 10.1007/s00103-021-03477-9. Epub 2022 Jan 11.
5
Viral hepatitis update: Progress and perspectives.
World J Gastroenterol. 2021 Jul 14;27(26):4018-4044. doi: 10.3748/wjg.v27.i26.4018.
6
Immunopotentiating and Delivery Systems for HCV Vaccines.
Viruses. 2021 May 25;13(6):981. doi: 10.3390/v13060981.
7
Hepatitis C Virus Vaccine: Challenges and Prospects.
Vaccines (Basel). 2020 Feb 17;8(1):90. doi: 10.3390/vaccines8010090.
8
Challenges and Promise of a Hepatitis C Virus Vaccine.
Cold Spring Harb Perspect Med. 2020 Feb 3;10(2):a036947. doi: 10.1101/cshperspect.a036947.
9
Approaches, Progress, and Challenges to Hepatitis C Vaccine Development.
Gastroenterology. 2019 Jan;156(2):418-430. doi: 10.1053/j.gastro.2018.08.060. Epub 2018 Sep 27.
10
The Rationale for a Preventative HCV Virus-Like Particle (VLP) Vaccine.
Front Microbiol. 2017 Nov 7;8:2163. doi: 10.3389/fmicb.2017.02163. eCollection 2017.

本文引用的文献

1
Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection.
Proc Natl Acad Sci U S A. 2003 May 27;100(11):6753-8. doi: 10.1073/pnas.1131929100. Epub 2003 May 14.
4
7
Perspectives on prophylactic and therapeutic immunization against hepatitis B and C viruses.
Transfus Clin Biol. 2001 Dec;8(6):467-70. doi: 10.1016/s1246-7820(01)00200-2.
9
Determinants of viral clearance and persistence during acute hepatitis C virus infection.
J Exp Med. 2001 Nov 19;194(10):1395-406. doi: 10.1084/jem.194.10.1395.
10
Hypervariable region 1 of hepatitis C virus: immunological decoy or biologically relevant domain?
Antiviral Res. 2001 Nov;52(2):153-9. doi: 10.1016/s0166-3542(01)00180-2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验